Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (7): 1-5.doi: 10.6040/j.issn.1671-7554.0.2019.072

   

Advances of cellular immunotherapy for hematologic malignancies

HUANG Xiaojun   

  1. Peking University Peoples Hospital;
    Peking University Institute of Hematology;
    National Clinical Research Center for Hematologic Disease;
    Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
  • Published:2022-09-27

PDF (PC)

71

Abstract: Immunotherapy has changed the therapeutic method and prognosis of malignant tumors. Hematopoietic stem cell transplantation is one of the earliest applied immunotherapy, which remains the essential treatment of many hematological malignancies. In recent years, new immunotherapy, such as CAR-T, PD-1 and NK cell therapy, has developed rapidly for the treatment of high-risk malignant hematological diseases, and has attracted attention from researchers all over the world. Cellular immunotherapy is suitable for patients with graft failure or contraindications, and is a less toxic alternative for relapsed/refractory patients. This paper reviews the advances of cellular immunotherapy for hematological malignancies.

Key words: Cellular immunotherapy, Hematologic malignancies, Review

CLC Number: 

  • R733.7
[1] Hu Y, He GL, Zhao XY, et al. Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation [J]. Oncoimmunology, 2017, 6(3): 1284721.
[2] Lv M, Zhao XS, Hu Y, et al. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation [J]. Am J Hematol, 2015, 90(1): 9-16.
[3] Chang YJ, Huang XJ. Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review [J]. Clin Transplant, 2011, 25(1): 13-23.
[4] Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies [J]. Bone Marrow Transplant, 2006, 38(4): 291-297.
[5] Huang XJ, Han W, Xu LP, et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease [J]. Chin Med J(Engl), 2004, 117(12): 1778-1785.
[6] Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies [J]. Clin Cancer Res, 2009, 15(14): 4777-4783.
[7] Wang Y, Liu QF, Xu LP, et al. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study [J]. Clin Cancer Res, 2016, 22(14): 3467-3476.
[8] Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study [J]. Blood, 2015, 125(25): 3956-3962.
[9] Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? [J]. Blood, 2014, 124(6): 843-850.
[10] Luo Y, Xiao H, Lai X, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT [J]. Blood, 2014, 124(17): 2735-2743.
[11] Wang Y, Wu DP, Liu QF, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants [J]. Leukemia, 2018, 32(2): 492-498.
[12] Luznik L, Engstrom LW, Iannone R, et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation [J]. Biol Blood Marrow Transplant, 2002, 8(3): 131-138.
[13] Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide [J]. Biol Blood Marrow Transplant, 2008, 14(6): 641-650.
[14] Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome [J]. Biol Blood Marrow Transplant, 2010, 16(4): 482-489.
[15] Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation [J]. J Clin Oncol, 2013, 31(10): 1310-1316.
[16] Harris DT, Kranz DM. Adoptive T Cell therapies: A comparison of T Cell receptors and chimeric antigen receptors [J]. Trends Pharmacol Sci, 2016, 37(3): 220-230.
[17] Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients [J]. Leukemia, 2017, 31(12): 2587-2593.
[18] Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas [J]. N Engl J Med, 2017, 377(26): 2545-2554.
[19] Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy [J]. Nat Med, 2018, 24(1): 20-28.
[20] Brudno JN, Somerville RP, Shi V, et al. Allogeneic T Cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic STEM-Cell transplantation without causing graft-versus-host disease [J]. J Clin Oncol, 2016, 34(10): 1112-1121.
[21] Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation [J]. Br J Haematol, 2017, 179(4): 598-605.
[22] Yifei Cheng, Chenhua Yan, Yu Wang, et al. Donor-derived CD19-targeted T cell infusion eliminates B cell acute lymphoblastic leukemia minimal residual disease with no response to donor lymphocytes after allogeneic hematopoietic stem cell transplantation [J]. Engineering, 2019.
[23] Luna JI, Grossenbacher SK, Murphy WJ, et al. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy [J]. Expert Opin Biol Ther, 2017, 17(3): 313-324.
[24] Sun H, Xu J, Huang Q, et al. Reduced CD160 expression contributes to impaired nk-cell function and poor clinical outcomes in patients with hcc [J]. Cancer Res, 2018, 78(23): 6581-6593.
[25] Cong J, Wang X, Zheng X, et al. Dysfunction of natural killer cells by fbp1-induced inhibition of glycolysis during lung cancer progression [J]. Cell Metab, 2018, 28(2): 243-255.
[26] Jiang W, Zhang C, Tian Z, et al. hIL-15-gene modified human natural killer cells(NKL-IL15)exhibit anti-human leukemia functions [J]. J Cancer Res Clin Oncol, 2018, 144(7): 1279-1288.
[27] Parkhurst MR, Riley JP, Dudley ME, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression [J]. Clin Cancer Res, 2011, 17(19): 6287-6297.
[28] Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy [J]. Nat Rev Cancer, 2008, 8(4): 299-308.
[29] Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cell infusion after human leukocyte antigen-haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia [J]. Biol Blood Marrow Transplant, 2016, 22(11): 2065-2076.
[30] Killig M, Friedrichs B, Meisig J, et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation [J]. Eur J Immunol, 2014, 44(9): 2822-2834.
[31] Curti A, Ruggeri L, Parisi S, et al. Larger size of donor alloreactive nk cell repertoire correlates with better response to nk cell immunotherapy in elderly acute myeloid leukemia patients [J]. Clin Cancer Res, 2016, 22(8): 1914-1921.
[1] Haipeng SI,Wencan ZHANG,Le LI,Xin ZHOU. Research advances on risk factors, diagnosis and treatment of Kümmell's disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 25-32.
[2] QI Meng, HUANG Yan, WU Shanshan, LIU Bo, ZHANG Siwei. Effects of single-energy metal artifact reduction algorithm: a systematic review and Meta-analysis [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 59-64.
[3] JIANG Baofa, DING Guoyong, LIU Xuena. Research progress on the relationship between floods and human health [J]. Journal of Shandong University (Health Sciences), 2018, 56(8): 21-28.
[4] MA Runmei, ZHANG Yi, WANG Yanwen, XU Dandan, SUN Zhiying, SHI Wanying, CUI Liangliang, LI Tiantian. A systematic review on association between particulate matter and blood glucose [J]. Journal of Shandong University (Health Sciences), 2018, 56(11): 27-33.
[5] SUN Yuanyuan, GAO Wei, CUI Ying, ZHANG Hong, JIAO Jianfen, LI Kan, XU Ruicai. A systematic review on the effects of venous access port and PICC in cancer patients undergoing chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(10): 73-81.
[6] LU Lu1,2, LI He1, YAN Yi3, GUO Jing1. Root resorption associated with self-ligating versus conventional ligating orthodontic bracket systems: a systematic review [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 104-108.
[7] ZHANG Lin1, HOU Yan-hong1, ZHANG Jian2, HU Jing1, ZHANG Jing1. Experimental study of anti-CD3/anti-EGFR bispecific antibody therapeutic activity against pancreatic cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 15-19.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd